Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
HPTN 102/PURPOSE 3
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
MVT-601A-006 MOXIE
The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.
Effects of the Contraceptive Implant in Women with Sickle Cell Disease (SCD CURE)
This research is being done to see if women who have sickle cell disease (SCD) experience any difference in their pain while using a hormonal implant as compared to when not using a hormonal implant (Nexplanon).
We are seeking women between the ages of 18 and 45 who have been diagnosed with SCD and have had at least 3 vaso-occlusive pain episodes in the previous 6 months. If you agree to join the study, you will be asked to complete the following research procedures: you will complete a 3-month “baseline” with no use of hormonal contraception (such as the birth control pill, ring, or injection), and then will have a contraceptive implant (Nexplanon) placed for 6 months. Your participation will last for a total of 9 months, with 3 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as the completion of a daily text message questionnaire.
Platform Trial
The phase 2/3 HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products (IP) for the treatment of ALS. IPs are tested in trial regimens (Regimen-Specific Appendix (RSA)). Patients will be randomized twice, first to one of the regimens, and second to the regimen study drug or placebo. Subjects will complete questionnaires, physical exams, motor tests and biological samples collection.
A Study of AAV2-GDNF in Adults with Moderate Parkinsons Disease (REGENERATE-PD)
Phase 2
The study is designed to evaluate the efficacy and safety of intraputaminal delivery of AAV2-GDNF gene therapy in subjects with moderate Parkinson's disease and demonstrate proof-of-concept. Subjects will be randomized to 1 of 2 treatment arms, AAV2-GDNF surgery or control surgery and will undergo screening, two baseline visits, perioperative procedures, and double-blind follow-up. Procedures include biological fluid sampling; MRI, CT, PET imaging, clinical assessments; and activity monitoring.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
